Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121–7.10.1038/leu.2010.60Search in Google Scholar PubMed PubMed Central
2. Pieri M, De Stefano A, Franceschini L, Rizzo M, Duranti F, Bernardini S, et al. Minimal tumor burden in haematological diseases: a step forward with quantitative assessment of Bence-Jones in nephelometry? Br J Haematol 2015; Dec 18. DOI: 10.1111/bjh.13878.Search in Google Scholar PubMed
3. Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic performance of quantitative κ and λ free light chain assays in clinical practice. Clin Chem 2005;51:878–81.10.1373/clinchem.2004.046870Search in Google Scholar PubMed
4. Drayson M, Carr-Smith H. Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis. Clin Chem Lab Med 2012;50:587–8.10.1515/cclm-2012-0037Search in Google Scholar PubMed
©2016 Walter de Gruyter GmbH, Berlin/Boston
